APOE ε4 - Medxy AI

APOE ε4, Age and Sex Converge to Disturb Anterior Olfactory Nucleus Physiology: Electrophysiologic Evidence for Early Alzheimer’s Vulnerability

By MedXY 11/05/2025

In vivo awake recordings in transgenic mice show APOE ε4 reduces neuronal excitability in the anterior olfactory nucleus (AON); adult females are more excitable than males (a sex difference lost with aging), while aging amplifies network oscillatory power — revealing interactions that may underlie early olfactory deficits in Alzheimer’s disease.

Neurology news Pathology & Lab Medicine Psychiatry Specialties

Amygdala Tau Pathology as a Key Contributor to Depressive Symptoms in Aging: Insights from Neuroimaging Studies

By MedXY 10/21/2025

Amygdala tau accumulation in cognitively normal older adults correlates with worsening depressive symptoms, especially in APOE ε4 carriers, highlighting its role in neuropsychiatric changes during aging.

Neurology news Specialties

APOE ε4 Allele as an Independent Predictor of Survival in Parkinson’s Disease Patients

By MedXY 10/21/2025

The APOE ε4 allele significantly reduces survival in Parkinson's disease patients independently of dementia, linked to mitochondrial dysfunction and ER stress in PD models.

Family Medicine & Nutrition Neurology news Specialties

APOE ε4 Allele: A Key Driver of Cognitive Decline and Neurodegeneration in Older Adults from the Democratic Republic of the Congo

By MedXY 10/21/2025

This study reveals that the APOE ε4 allele is linked to increased dementia prevalence, cognitive deficits, brain atrophy, and plasma biomarkers of neurodegeneration in older adults in the DRC, emphasizing its critical role in African populations.

Internal Medicine Neurology news

Unraveling Blood-Based Biomarkers in Neurodegenerative Diseases: Insights from the Young Finns Study on Intergenerational and Metabolic Influences

By MedXY 10/20/2025

This cohort study from the Young Finns Study elucidates factors influencing blood-based biomarkers for neurodegenerative diseases, highlighting age, APOE ε4 genotype, kidney function, metabolic parameters, and notable intergenerational associations.

Clinical Updates Family Medicine & Nutrition Neurology news Specialties

Walking and Dietary Interventions Offer Cognitive Protection in APOE ε4 Carriers: New Evidence from Longitudinal and Multinational Trials

By MedXY 07/30/2025

Regular walking and lifestyle interventions slow cognitive decline, especially in APOE ε4 carriers at heightened Alzheimer’s risk, with effects pronounced in women. Evidence underscores the value of simple activity and healthy diet for at-risk older adults.